StockData

Dianthus Therapeutics, Inc. (DNTH) stock

DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$92.48+3.18 (+3.56%)

Close on Nov 12, 2026Market cap $5.17BP/E –Yield 0.00%

Dianthus Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Dianthus Therapeutics's ebitda for the twelve months ending Jun 30, 2023 was -$37.05M. For fiscal 2022 it was -$27.78M. The highest annual figure on record is -$9.26M in fiscal 2016.

Annual ebitda

PeriodPeriod endValueChange
FY2022Dec 31, 2022-$27.78M–
FY2021Dec 31, 2021-$72.67M–
FY2020Dec 31, 2020-$76.72M–
FY2019Dec 31, 2019-$81.13M–
FY2018Dec 31, 2018-$59.09M–
FY2017Dec 31, 2017-$35.35M–
FY2016Dec 31, 2016-$9.26M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2023Jun 30, 2023-$11.78M–
Q1 FY2023Mar 31, 2023-$7.26M–
Q4 FY2022Dec 31, 2022-$10.23M–
Q3 FY2022Sep 30, 2022-$7.78M–
Q2 FY2022Jun 30, 2022-$17.61M–
Q1 FY2022Mar 31, 2022-$23.32M–
Q4 FY2021Dec 31, 2021-$19.61M–
Q3 FY2021Sep 30, 2021-$17.71M–
Q2 FY2021Jun 30, 2021-$17.13M–
Q1 FY2021Mar 31, 2021-$18.22M–
Q4 FY2020Dec 31, 2020-$18.57M–
Q3 FY2020Sep 30, 2020-$17.89M–
Q2 FY2020Jun 30, 2020-$19.52M–
Q1 FY2020Mar 31, 2020-$20.75M–
Q4 FY2019Dec 31, 2019-$24.15M–
Q3 FY2019Sep 30, 2019-$22.16M–
Q2 FY2019Jun 30, 2019-$18.89M–
Q1 FY2019Mar 31, 2019-$15.93M–
Q4 FY2018Dec 31, 2018-$17.57M–
Q3 FY2018Sep 30, 2018-$16.49M–
Q2 FY2018Jun 30, 2018-$13.87M–
Q1 FY2018Mar 31, 2018-$11.16M–
Q4 FY2017Dec 31, 2017-$8.04M–
Q3 FY2017Sep 30, 2017-$6.90M–

More Dianthus Therapeutics figures

See a number that looks wrong?